Wouter Joustra MSc
General Partner
Beacon Therapeutics is an ophthalmic gene therapy company founded to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
Beacon Therapeutics is an ophthalmic gene therapy company founded to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
The company works in three main disease areas: X-linked retinitis pigmentosa (XLRP), Dry Age-related Macular Degeneration (dAMD) and Cone Rod Dystrophy (CRD).
Human Health
UK
Rolling Stock Yard, 2nd floor,
188 York Way,
Kings Cross,
London, N7 9AS
US
14193 NW 119th Terrace,
Suite #20,
Alachua, Florida 32615
US
100 CambridgePark Drive,
Suite 2200
Cambridge, MA 02140
Industry
Biotech
Status
Current
Location
UK
Beacon continues to make significant progress towards delivering a commercially sustainable gene therapy for inherited retinal diseases, with laru-zova now advancing through late-stage clinical development. Our experience in ocular gene therapy, combined with deep scientific expertise and a focused clinical strategy, has positioned Beacon as a leader in the space. In Forbion, Beacon has a strategic partner providing not just capital, but also know-how, to support a company pushing the boundaries of what is possible to develop transformative medicines for devastating blinding diseases.Lance Baldo
CEO of Beacon Therapeutics
